Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.57 |
| ▸ | CCR5 | P51681 | 2/20 | 0.57 |
| ▸ | CCR8 | P51685 | 2/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ROS1 | P08922 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27344644 | 0.86 | CCR1 (0.76) | CCR1CCR5CCR8ABL1BCR | |
| SCHEMBL31695263 | 0.86 | CCR1 (0.76) | CCR1CCR5CCR8ABL1BCR | |
| SCHEMBL6703629 | 0.82 | CCR1 (0.53) | CCR1CCR5CCR8NPC1RAB9A | |
| SCHEMBL6807225 | 0.82 | CCR1 (0.70) | CCR1CCR5CCR8ABL1BCR | |
| SCHEMBL29463685 | 0.82 | CCR1 (0.70) | CCR1CCR5CCR8ABL1BCR | |
| SCHEMBL14082313 | 0.81 | RAB9A (0.63) | ABL1BCRNPC1RAB9AKDM4E | |
| SCHEMBL9014019 | 0.81 | CCR1 (0.80) | CCR1CCR5CCR8DYRK1AABL1 | |
| SCHEMBL14554394 | 0.81 | CCR1 (0.80) | CCR1CCR5CCR8DYRK1AABL1 | |
| SCHEMBL9014003 | 0.81 | CCR1 (0.80) | CCR1CCR5CCR8DYRK1AABL1 | |
| SCHEMBL12335822 | 0.80 | NPC1 (0.59) | CCR1CCR5CCR8DYRK1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574870-B | Luminescent gold (III) compound containing bidentate ligand for organic light-emitting device and preparation method thereof | THE UNIVERSITY OF HONG KONG (CN) | 2016-05-18 | — | — | CN | claimed |
| US-8372977-B2 | Luminescent gold(III) compounds containing bidentate ligand for organic light-emitting devices and their preparation | THE UNIVERSITY OF HONG KONG (CN) | 2013-02-12 | — | — | US | claimed |
| US-20110012093-A1 | LUMINESCENT GOLD(III) COMPOUNDS CONTAINING BIDENTATE LIGAND FOR ORGANIC LIGHT-EMITTING DEVICES AND THEIR PREPARATION | THE UNIVERSITY OF HONG KONG (CN) | 2011-01-20 | — | — | US | claimed |
| CN-109912567-A | A kind of biaryl pyrrole derivatives compound and preparation method thereof | 台州职业技术学院 | 2019-06-21 | — | — | CN | disclosed |
| CN-102574870-B | Luminescent gold (III) compound containing bidentate ligand for organic light-emitting device and preparation method thereof | THE UNIVERSITY OF HONG KONG (CN) | 2016-05-18 | — | — | CN | disclosed |
| US-8372977-B2 | Luminescent gold(III) compounds containing bidentate ligand for organic light-emitting devices and their preparation | THE UNIVERSITY OF HONG KONG (CN) | 2013-02-12 | — | — | US | disclosed |
| CN-102574870-A | Luminescent gold (III) compound containing bidentate ligand for organic light-emitting device and preparation method thereof | UNIV HONG KONG | 2012-07-11 | — | — | CN | disclosed |
| WO-2011006353-A1 | LUMINESCENT GOLD(III) COMPOUNDS CONTAINING BIDENTATE LIGAND FOR ORGANIC LIGHT-EMITTING DEVICES AND THEIR PREPARATION | THE UNIVERSITY OF HONG KONG (CN) | 2011-01-20 | — | — | WO | disclosed |
| US-20110012093-A1 | LUMINESCENT GOLD(III) COMPOUNDS CONTAINING BIDENTATE LIGAND FOR ORGANIC LIGHT-EMITTING DEVICES AND THEIR PREPARATION | THE UNIVERSITY OF HONG KONG (CN) | 2011-01-20 | — | — | US | disclosed |
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| EP-1355870-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-6521643-B1 | Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002062753-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| EP-1157022-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000049015-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | TGFBR1, TGFB1, TGFBR2 | CCR1 509/4885CCR5 1105/4885CCR8 1652/4885 |
| US-20110012093-A1 | LUMINESCENT GOLD(III) COMPOUNDS CONTAINING BIDENTATE LIGAND FOR ORGANIC LIGHT-EMITTING DEVICES AND THEIR PREPARATION | CHRM1, CHRM5, CHRM2 | CCR1 741/4885CCR5 113/4885CCR8 562/4885 |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | TGFBR1, SMAD3, TGFBR2 | CCR1 824/4885CCR5 1748/4885CCR8 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.